Department of Pathology, Moffitt Cancer Center 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Head Neck Pathol. 2024 Feb 23;18(1):11. doi: 10.1007/s12105-024-01620-x.
Metastatic carcinoma of unknown primary origin to the head and neck lymph nodes (HNCUP) engenders unique diagnostic considerations. In many cases, the detection of a high-risk human papillomavirus (HR-HPV) unearths an occult oropharyngeal squamous cell carcinoma (SCC). In metastatic HR-HPV-independent carcinomas, other primary sites should be considered, including cutaneous malignancies that can mimic HR-HPV-associated SCC. In this context, ultraviolet (UV) signature mutations, defined as ≥ 60% C→T substitutions with ≥ 5% CC→TT substitutions at dipyrimidine sites, identified in tumors arising on sun exposed areas, are an attractive and underused tool in the setting of metastatic HNCUP.
A retrospective review of institutional records focused on cases of HR-HPV negative HNCUP was conducted. All cases were subjected to next generation sequencing analysis to assess UV signature mutations.
We identified 14 HR-HPV negative metastatic HNCUP to either the cervical or parotid gland lymph nodes, of which, 11 (11/14, 79%) had UV signature mutations, including 4 (4/10, 40%) p16 positive cases. All UV signature mutation positive cases had at least one significant TP53 mutation and greater than 20 unique gene mutations.
The management of metastatic cutaneous carcinomas significantly differs from other HNCUP especially metastatic HR-HPV-associated SCC; therefore, the observation of a high percentage of C→T with CC →TT substitutions should be routinely incorporated in next generation sequencing reports of HNCUP. UV mutational signatures testing is a robust diagnostic tool that can be utilized in daily clinical practice.
头颈部淋巴结(HNCUP)不明原发灶转移性癌引起独特的诊断考虑。在许多情况下,检测高危型人乳头瘤病毒(HR-HPV)会发现隐匿性或口咽鳞状细胞癌(SCC)。在转移性 HR-HPV 无关的癌中,应考虑其他原发部位,包括可能模仿 HR-HPV 相关 SCC 的皮肤恶性肿瘤。在这种情况下,在暴露于紫外线(UV)的肿瘤中发现的 UV 特征性突变(定义为≥60% C→T 取代,≥5% CC→TT 取代在二嘧啶位点)是转移性 HNCUP 中一种有吸引力但未被充分利用的工具。
对机构记录进行回顾性审查,重点是 HR-HPV 阴性 HNCUP 病例。所有病例均进行下一代测序分析,以评估 UV 特征性突变。
我们确定了 14 例 HR-HPV 阴性转移性 HNCUP 至颈部或腮腺淋巴结,其中 11 例(11/14,79%)有 UV 特征性突变,包括 4 例(4/10,40%)p16 阳性病例。所有 UV 特征性突变阳性病例至少有一个显著的 TP53 突变和大于 20 个独特的基因突变。
转移性皮肤癌的治疗与其他 HNCUP 显著不同,特别是转移性 HR-HPV 相关 SCC;因此,应常规将 C→T 与 CC→TT 取代的高百分比纳入 HNCUP 的下一代测序报告中。UV 突变特征测试是一种强大的诊断工具,可在日常临床实践中使用。